Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG (Nasdaq: CRSP) files detailed reports with the U.S. Securities and Exchange Commission that document its financial condition, clinical pipeline progress, collaborations, and capital markets activity. On this SEC filings page, Stock Titan aggregates CRSP’s regulatory documents and pairs them with AI-powered summaries to help readers interpret the implications of each filing.
For a gene editing biopharmaceutical company like CRISPR Therapeutics, annual reports on Form 10-K and quarterly reports on Form 10-Q typically describe the status of programs such as CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, in vivo liver editing candidates like CTX310 and CTX320, SyNTase-based CTX460 for alpha-1 antitrypsin deficiency, zugo-cel in autoimmune and oncology indications, and siRNA collaborations such as SRSD107/CTX611 with Sirius Therapeutics. These reports also outline risk factors, research and development priorities, and collaboration structures with partners including Vertex Pharmaceuticals.
Current reports on Form 8-K provide more focused updates on material events, such as quarterly financial results, business updates, and capital-raising actions. For example, recent 8-K filings describe the announcement of quarterly results and the use of an at-the-market equity program under an Open Market Sale Agreement with Jefferies to offer additional common shares under a shelf registration statement.
Investors can also use this page to monitor registration statements, prospectus supplements, and other offering-related filings that detail how CRISPR Therapeutics issues new equity, as well as any proxy materials that address governance and shareholder matters. Stock Titan’s tools surface new CRSP filings in near real time from EDGAR and apply AI-generated highlights so readers can quickly locate key disclosures on clinical data, collaboration terms, cash runway, and share issuance without reading every page.
CRISPR Therapeutics (CRSP) Form 4: On October 16, 2025, the CEO and director reported the vesting and settlement of 100,000 restricted stock units into common shares. On October 17, 2025, 50,895 common shares were sold at $67.91 to cover tax withholding mandated by company policy. Following these transactions, holdings were 254,201 common shares directly and 85,662 indirectly via The Kulkarni 2023 GRAT. The RSU grant leaves 300,000 RSUs scheduled to vest annually through October 2028.
CRISPR Therapeutics (CRSP) reported an insider equity event. The company’s General Counsel and Secretary had 2,114 restricted stock units settle into common shares on 10/13/2025. On 10/14/2025, 1,076 shares were sold at $66.6 to cover tax withholding under the company’s RSU Settlement Policy, described as a non-discretionary sale.
Following these transactions, the insider directly owned 83,402 common shares. A remaining balance of 2,113 RSUs is reported outstanding.
CRISPR Therapeutics AG filed a prospectus supplement to offer and sell, from time to time and at its sole discretion through Jefferies as sales agent, additional common shares with an aggregate offering price of $600,000,000. The common shares will be issued under the company’s automatically effective shelf registration statement on Form S-3ASR (File No. 333-281262) filed on August 5, 2024.
The filing notes the engagement of Jefferies LLC under an existing Open Market Sale Agreement and includes a legal opinion from Walder Wyss AG as Exhibit 5.1. This action provides the company with the ability to raise capital over time via open market sales, subject to applicable securities laws.
CRISPR Therapeutics AG launched an at‑the‑market offering of up to $600,000,000 of common shares, to be sold from time to time through Jefferies as sales agent under an existing Sales Agreement. Sales may be made in transactions deemed an “at the market offering” under Rule 415(a)(4). Jefferies will use commercially reasonable efforts and earn a commission of up to 3.0% of the gross sales price; there is no escrow arrangement.
The company expects to use potential net proceeds to fund research and clinical development, platform extensions, manufacturing infrastructure, working capital and general corporate purposes. Estimated offering expenses are approximately $6.4 million, which include a Swiss federal securities issuance stamp tax of 1%.
The prospectus provides an illustrative dilution scenario assuming sales at $68.29 per share, showing immediate dilution of $44.76 per share to new investors. Common shares outstanding were 88,376,439 as of June 30, 2025.
CRISPR Therapeutics (CRSP) insider activity: The company’s Chief Executive Officer and Director reported the vesting of 8,334 restricted stock units on 10/13/2025, increasing direct holdings. On 10/14/2025, 4,242 common shares were sold at $66.6 to satisfy tax withholding mandated by the company’s RSU Settlement Policy.
Following these transactions, directly held common shares were 205,096, with an additional 85,662 held indirectly via The Kulkarni 2023 GRAT. The RSU grant was part of a 25,000‑share award vesting in three annual tranches.
CRISPR Therapeutics (CRSP) reported an insider equity award. The Chief Executive Officer and Director received a stock option covering 49,500 Common Shares on October 3, 2025 with an exercise price of $67.74 per share. The option vests in 48 equal monthly installments, beginning November 3, 2025, and expires on October 3, 2035. The filing lists the holding as Direct ownership.
CRISPR Therapeutics AG (CRSP)16,500 common shares with an exercise price of $67.74 on October 3, 2025. The option expires on October 3, 2035.
The award vests in 48 equal monthly installments, beginning November 3, 2025. Following the grant, 16,500 derivative securities were beneficially owned, shown as Direct (D) ownership.
CRISPR Therapeutics AG reported an insider transaction on Form 4 for its Chief Financial Officer. The filing discloses a stock option grant covering 16,500 Common Shares at an exercise price of $67.74 on October 3, 2025. The option vests in 48 equal monthly installments beginning November 3, 2025 and carries an expiration date of October 3, 2035. The reporting person holds 16,500 derivative securities directly following the transaction.
On 09/17/2025 Samarth Kulkarni, Chief Executive Officer and a Director of CRISPR Therapeutics AG (CRSP), reported a transaction on Form 4 showing he donated 6,000 common shares to a donor-advised fund. The Form 4 shows 201,004 shares beneficially owned directly after the transaction and 85,622 shares indirectly held through the Kulkarni 2023 GRAT. The filing is signed on 09/19/2025 and notes the donation as the reason for the disposition; the reported price is $0.00, indicating a charitable transfer rather than a sale for proceeds.
Samarth Kulkarni, Chief Executive Officer and director of CRISPR Therapeutics AG (CRSP), had 25,000 restricted stock units vest on 08/16/2025, each converting to one common share. To satisfy tax withholding required by the company's RSU Settlement Policy, the reporting person sold 13,081 shares on 08/18/2025 at a price of $58.15 per share. After these transactions the reporting person directly beneficially owns 207,004 common shares and indirectly owns 85,622 common shares through the Kulkarni 2023 GRAT. The sale was described as mandated to cover tax withholding and not a discretionary trade.
FAQ
What is the current stock price of Crispr Therapeut (CRSP)?
What is the market cap of Crispr Therapeut (CRSP)?
